Therapeutic Development and Preclinical Studies – TDPS
Applications reviewed in TDPS will typically focus on preclinical work in animal models, where research efforts are focused on the generation/development of novel therapies within fields such as cardiac, vascular systems and related regulatory organ systems including hemostasis and thrombosis. Proposed research may involve efforts to develop new understanding/perspectives associated with cardiac, vascular or blood-related dysfunction/toxicology. Aims may focus on device optimization, therapeutic target development and drug discovery programs.
Review Dates
Topics
- In research areas focused on the generation/development of novel therapies within fields such as cardiac, vascular systems and related regulatory organ systems, including hemostasis and thrombosis; TDPS reviews
• preclinical studies, proof of concept (POC) and mechanism-of-action (MOA) studies, and
• research aimed at providing insight toward the development of novel therapeutic strategies; - Resuscitation studies evaluated in animal model systems;
- In areas focused on the generation/development of novel therapies within fields such as cardiac, vascular systems and related regulatory organ systems, including hemostasis and thrombosis; TDPS reviews
• dosing studies in pre-clinical models: large and small animal systems. Studies may involve varied proposed therapeutic approaches including small molecule, cell-based, viral, peptide, antibody as well as the evaluation of microbiome/microbiota-based strategies; - In areas focusing on cardiac, vascular systems and related regulatory organ systems, including hemostasis and thrombosis; TDPS reviews
• Target development: including efforts to discover and/or characterize potential therapeutic targets;
• Preclinical and population “-omic” studies: those involving genomic, transcriptomic, metabolomic, etc.
• Preclinical device development and safety studies in animal models: proposed research may involve assist devices, bioengineered technologies, stem-cell based treatments; - Development and evaluation of interventions and biomedical devices: those aimed at diagnosing and/or treating cardiac, vascular and hematologic disorders.
Shared Interests and Overlaps
TDPS and Clinical Integrative Cardiovascular and Hematological Sciences (CCHS) have shared interests in human, patient-oriented studies. Applications that emphasize exploratory or pre-clinical studies and are conducted in animal models prior to validation studies within humans/human-based systems will be reviewed in TDPS.
TDPS and Integrative Vascular Physiology and Pathology (IVPP) have shared interests in the mechanisms of action, identifying potential therapeutic targets and/or delivering therapeutic agents aimed at treating disorders such as hypertension and vascular stiffness. Applications that emphasize mechanisms of action of disorders, hypertension and vascular stiffness will be reviewed in IVPP. Applications that emphasize characterization mechanisms of action towards identifying potential therapeutic targets and/or delivering therapeutic agents in preclinical models will be reviewed in TDPS.
TDPS and Atherosclerosis and Vascular Inflammation (AVI) have shared interests in cardiovascular inflammatory disorders. Applications that emphasize mechanisms of action of cardiovascular inflammatory disorders such as atherosclerosis, vasculitis, myocarditis will be reviewed in AVI. Applications that emphasize mechanisms of action towards identifying potential therapeutic targets and/or delivering therapeutic agents aimed at treating cardiovascular inflammatory disorders such as atherosclerosis, vasculitis, myocarditis will be reviewed in TDPS.
TDPS and Integrative Myocardial Physiology/Pathophysiology A (MPPA) have shared interests in topics related to heart dysfunction including cardiac hypertrophy, heart failure and valvular disease. Applications that emphasize the characterization of underlying mechanisms of disease will be reviewed in MPPA. Applications seeking to characterize mechanisms of disease linked to the discovery of potential therapeutic targets and/or delivering therapeutic agents aimed to treat or prevent heart dysfunction and valvular disease will be reviewed in TDPS.
TDPS and Integrative Myocardial Physiology/Pathophysiology B (MPPB) have shared interests in topics related to ischemia/reperfusion (I/R) tissue injury, arrhythmogenesis and drug induced toxicity. Applications that emphasize the characterization of underlying mechanisms of disease will be reviewed in MPPB. Applications seeking to characterize mechanisms of disease linked to the discovery of potential therapeutic targets and/or delivering therapeutic agents aimed to treat or prevent I/R-related heart dysfunction, arrhythmogenesis and drug toxicity will be reviewed in TDPS.
